Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

CORT

Corcept Therapeutics Inc

Dec 20 • 04:00PM ET

51.40

Dollar change +0.25
Percentage change 0.49	%

Healthcare • Biotechnology • USA • NASD

Peers: NBIX SRPT TGTX MDGL ARDX ANAB VKTX AKBA LGND PSTV

| Held by: IJR VTI IWM VB VXF VBK SPSM FBT IWO IJT

Scroll to Statements

Index	RUT	P/E	40.88	EPS (ttm)	1.26	Insider Own	13.87%	Shs Outstand	104.70M	Perf Week	-7.22%
Market Cap	5.41B	Forward P/E	26.87	EPS next Y	1.91	Insider Trans	-0.62%	Shs Float	90.24M	Perf Month	-8.36%
Income	140.46M	PEG	-	EPS next Q	0.38	Inst Own	82.24%	Short Float	18.90%	Perf Quarter	19.67%
Sales	628.55M	P/S	8.61	EPS this Y	44.68%	Inst Trans	-1.36%	Short Ratio	17.24	Perf Half Y	68.03%
Book/sh	6.10	P/B	8.42	EPS next Y	40.66%	ROA	20.38%	Short Interest	17.05M	Perf Year	66.45%
Cash/sh	3.61	P/C	14.23	EPS next 5Y	-	ROE	25.53%	52W Range	20.84 - 62.22	Perf YTD	58.25%
Dividend Est.	-	P/FCF	37.95	EPS past 5Y	9.67%	ROI	21.77%	52W High	-17.39%	Beta	0.55
Dividend TTM	-	Quick Ratio	3.64	Sales past 5Y	14.14%	Gross Margin	98.44%	52W Low	146.64%	ATR (14)	2.65
Dividend Ex-Date	-	Current Ratio	3.70	EPS Y/Y TTM	56.02%	Oper. Margin	22.81%	RSI (14)	37.49	Volatility	4.88% 4.37%
Employees	352	Debt/Eq	0.01	Sales Y/Y TTM	39.67%	Profit Margin	22.35%	Recom	1.00	Target Price	74.90
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	46.33%	Payout	0.00%	Rel Volume	2.48	Prev Close	51.15
Sales Surprise	6.15%	EPS Surprise	45.44%	Sales Q/Q	47.69%	Earnings	Oct 30 AMC	Avg Volume	988.85K	Price	51.40
SMA20	-10.36%	SMA50	-4.05%	SMA200	38.77%	Trades		Volume	2,456,297	Change	0.49%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-06-23	Upgrade	Truist	Hold → Buy	$29 → $38
Apr-11-23	Initiated	SVB Securities	Market Perform	$25
Apr-04-23	Initiated	Piper Sandler	Overweight	$27
Feb-15-23	Downgrade	Jefferies	Buy → Hold	$35 → $22
Aug-01-22	Downgrade	Truist	Buy → Hold	$30
Jul-27-22	Upgrade	Jefferies	Hold → Buy	$21 → $35
Jun-27-22	Resumed	Canaccord Genuity	Buy	$30 → $34
Feb-02-22	Initiated	Canaccord Genuity	Buy	$30
Jan-28-22	Initiated	Truist	Buy	$30
Aug-05-20	Downgrade	Jefferies	Buy → Hold	$16
Sep-24-19	Initiated	Jefferies	Buy	$20
Sep-06-19	Initiated	H.C. Wainwright	Buy	$18
Feb-04-19	Downgrade	B. Riley FBR	Buy → Neutral	$22 → $12
Aug-10-18	Reiterated	Stifel	Hold	$20 → $11
May-31-18	Downgrade	Stifel	Buy → Hold	$20
Mar-09-18	Initiated	B. Riley FBR, Inc.	Buy	$30
Aug-31-17	Initiated	Stifel	Buy	$20
Feb-02-17	Initiated	Ladenburg Thalmann	Buy	$14
Apr-21-15	Initiated	FBR Capital	Outperform	$12
Jan-13-14	Downgrade	Stifel	Buy → Hold

Show Previous Ratings

Dec-17-24 05:16AM	Corcept Therapeutics Cushings syndrome therapy shows promise in Phase III trial (Clinical Trials Arena)
Dec-16-24 08:00AM	Corcepts Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with Hypercortisolism (Business Wire)
Dec-13-24 08:53AM	Corcept Therapeutics' FDA-Approved Korlym Hits Main Goal In Cushing's Syndrome Patients With Difficult-To-Control Diabetes (Benzinga)
Dec-12-24 04:05PM	Corcept Announces Positive Results in Treatment Phase of CATALYST Trial in Patients With Hypercortisolism (Cushings Syndrome) and Difficult-to-Control Diabetes (Business Wire) -6.25%
Dec-11-24 04:05PM	Corcept Announces Results From Phase 2 Study of Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (ALS) (Business Wire)
03:06PM	Loading…
03:06PM	NewAmsterdam Pharma Stock Hits 90-Plus RS Rating (Investor's Business Daily)
09:50AM	Here's Why Corcept Therapeutics (CORT) is a Strong Momentum Stock (Zacks)
Dec-09-24 12:45PM	Corcept (CORT) is an Incredible Growth Stock: 3 Reasons Why (Zacks)
Dec-06-24 09:55AM	Wall Street Analysts See a 26.05% Upside in Corcept (CORT): Can the Stock Really Move This High? (Zacks)
Nov-29-24 11:31AM	Corcept (CORT) Up 19.7% Since Last Earnings Report: Can It Continue? (Zacks)
Nov-25-24 09:50AM	Why Corcept Therapeutics (CORT) is a Top Momentum Stock for the Long-Term (Zacks)
Nov-21-24 12:45PM	3 Reasons Growth Investors Will Love Corcept (CORT) (Zacks)
Nov-20-24 09:55AM	Wall Street Analysts Think Corcept (CORT) Could Surge 37.91%: Read This Before Placing a Bet (Zacks)
Nov-05-24 12:45PM	Here is Why Growth Investors Should Buy Corcept (CORT) Now (Zacks)
12:00PM	Corcept (CORT) Upgraded to Strong Buy: Here's Why (Zacks)
09:15AM	Loading…
09:15AM	Corcept Therapeutics Incorporated (CORT) Soars to 52-Week High, Time to Cash Out? (Zacks)
Nov-04-24 09:55AM	Wall Street Analysts Believe Corcept (CORT) Could Rally 56.66%: Here's is How to Trade (Zacks) +5.12%
Nov-01-24 12:20PM	Earnings Estimates Moving Higher for Corcept (CORT): Time to Buy? (Zacks)
08:17AM	Corcepts relacorilant GRADIENT trial misses primary endpoint (Clinical Trials Arena)
Oct-31-24 05:01AM	Corcept Therapeutics Inc (CORT) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
Oct-30-24 06:00PM	Corcept Therapeutics (CORT) Tops Q3 Earnings and Revenue Estimates (Zacks)
04:58PM	Corcept: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Corcept Therapeutics Announces Third Quarter Financial Results, Positive Results From Phase 3 GRADIENT Trial in Patients With Cushings Syndrome and Provides Corporate Update (Business Wire)
Oct-23-24 05:05PM	Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call (Business Wire)
Oct-21-24 03:41AM	Strength Seen in Corcept (CORT): Can Its 5.5% Jump Turn into More Strength? (Zacks)
Oct-17-24 09:55AM	Wall Street Analysts See a 43.01% Upside in Corcept (CORT): Can the Stock Really Move This High? (Zacks)
Oct-15-24 08:34AM	Implied Volatility Surging for Corcept Therapeutics (CORT) Stock Options (Zacks)
Oct-01-24 09:55AM	Wall Street Analysts Think Corcept (CORT) Could Surge 41.31%: Read This Before Placing a Bet (Zacks)
Sep-30-24 03:01PM	Corcept Therapeutics' Commercial Drug Korlym Sales Impress Despite Increased Competition, Analyst Boosts Price Forecast (Benzinga) +5.35%
Sep-25-24 07:39AM	Does Corcept Therapeutics (CORT) Have a Long Runway for Growth? (Insider Monkey)
07:53AM	Loading…
Sep-19-24 07:53AM	Corcept (CORT) Moves 6.5% Higher: Will This Strength Last? (Zacks)
Sep-10-24 08:46AM	Do Options Traders Know Something About Corcept (CORT) Stock We Don't? (Zacks)
Aug-28-24 11:30AM	Corcept (CORT) Down 4% Since Last Earnings Report: Can It Rebound? (Zacks)
Aug-27-24 12:00PM	Corcept (CORT) Upgraded to Buy: Here's Why (Zacks)
Aug-16-24 09:55AM	Wall Street Analysts Believe Corcept (CORT) Could Rally 70.58%: Here's is How to Trade (Zacks)
Aug-01-24 09:15AM	Corcept Therapeutics Incorporated (CORT) Hits Fresh High: Is There Still Room to Run? (Zacks)
Jul-31-24 12:20PM	Can Corcept (CORT) Run Higher on Rising Earnings Estimates? (Zacks) +7.06%
12:00PM	Are You Looking for a Top Momentum Pick? Why Corcept Therapeutics (CORT) is a Great Choice (Zacks)
09:55AM	Wall Street Analysts See a 37.6% Upside in Corcept (CORT): Can the Stock Really Move This High? (Zacks)
Jul-30-24 10:42AM	Corcept (CORT) Q2 Earnings & Revenues Surpass Estimates (Zacks)
Jul-29-24 05:55PM	Corcept Therapeutics (CORT) Q2 Earnings and Revenues Beat Estimates (Zacks)
04:54PM	Corcept: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-22-24 04:05PM	Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call (GlobeNewswire)
Jul-16-24 08:50AM	What Makes Corcept (CORT) a Good Fit for 'Trend Investing' (Zacks)
Jun-26-24 02:11PM	7 Biotech Stocks to Boost Your Portfolio to Peak Health (InvestorPlace)
11:13AM	Corcept (CORT) Shares Rise 20% in Three Months: Here's Why (Zacks)
06:00AM	Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for June 2024 (InvestorPlace)
Jun-24-24 04:15PM	Corcept Announces Presentation of Results From Prevalence Phase of CATALYST Clinical Trial at American Diabetes Association's Scientific Sessions (GlobeNewswire)
Jun-19-24 07:39AM	What Makes Corcept Therapeutics (CORT) a Good Investment Bet? (Insider Monkey)
Jun-14-24 09:50AM	Corcept Therapeutics (CORT) is a Top-Ranked Momentum Stock: Should You Buy? (Zacks) -8.06%
Jun-13-24 05:35PM	Teva sues Corcept over mifepristone 'monopoly' for rare disorder (Reuters)
Jun-06-24 02:58AM	Insider Sale: Chief Development Officer William Guyer Sells 10,000 Shares of Corcept ... (GuruFocus.com)
Jun-03-24 08:00AM	Corcept Therapeutics Announces Presentations of Results of Pivotal Phase 3 GRACE Trial Evaluating Relacorilant in Patients with Hypercortisolism (Cushing's Syndrome) (GlobeNewswire)
May-31-24 11:31AM	Corcept (CORT) Up 24.5% Since Last Earnings Report: Can It Continue? (Zacks)
03:12AM	Insider Sale: Chief Development Officer William Guyer Sells 30,000 Shares of Corcept ... (GuruFocus.com)
May-29-24 11:16AM	Corcept (CORT) Rises as Cushing's Syndrome Study Meets Goal (Zacks)
May-28-24 08:00AM	Corcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients With Hypercortisolism (Cushing's Syndrome) (GlobeNewswire) +14.86%
May-16-24 03:12AM	Corcept Therapeutics Insider Sold Shares Worth $1,400,000, According to a Recent SEC Filing (MT Newswires)
May-13-24 04:01AM	Pipeline Moves: Phase III completion for Corcepts relaorilant (Clinical Trials Arena)
May-02-24 11:45AM	Corcept (CORT) Q1 Earnings & Revenues Surpass Estimates (Zacks)
10:48AM	Corcept Therapeutics Incorporated (NASDAQ:CORT) Q1 2024 Earnings Call Transcript (Insider Monkey)
08:30AM	Truist Lifts Corcept Therapeutics' PT to $44 From $42 After Raised Kolym Guidance, Keeps Buy Rating (MT Newswires)
08:01AM	Q1 2024 Corcept Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
03:41AM	Corcept Therapeutics Inc (CORT) Q1 2024 Earnings Call Transcript Highlights: Strong Growth Amid ... (GuruFocus.com)
May-01-24 05:50PM	Corcept Therapeutics Inc (CORT) Outperforms Analyst Estimates in Q1 2024 (GuruFocus.com)
04:40PM	Corcept: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-29-24 08:00AM	Corcept Completes Enrollment in Phase 4 CATALYST Trial (GlobeNewswire)
Apr-24-24 04:05PM	Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call (GlobeNewswire)
Apr-23-24 12:12PM	Corcept (CORT) Posts Positive Data From Cushing's Syndrome Study (Zacks)
Apr-22-24 08:00AM	Corcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing's Syndrome (GlobeNewswire)
Apr-17-24 12:00PM	Corcept (CORT) Upgraded to Strong Buy: Here's What You Should Know (Zacks)
Apr-16-24 11:34AM	Corcept (CORT) Completes Enrollment in Phase II ALS Study (Zacks)
Apr-15-24 08:00AM	Corcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS) (GlobeNewswire)
Apr-09-24 11:09AM	Corcept (CORT) Completes Enrollment in Ovarian Cancer Study (Zacks) +5.08%
Apr-08-24 08:00AM	Corcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer (GlobeNewswire)
Apr-01-24 08:00AM	Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing's Syndrome (GlobeNewswire)
Mar-25-24 10:20AM	Will Corcept (CORT) Bank on Korlym in 2024 Amid Stiff Rivalry? (Zacks)
Feb-16-24 01:33PM	Corcept (CORT) Q4 Earnings Beat Estimates, Korlym Sales Grow (Zacks) -7.15%
09:04AM	Corcept Therapeutics Incorporated (NASDAQ:CORT) Q4 2023 Earnings Call Transcript (Insider Monkey)
08:57AM	Q4 2023 Corcept Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-15-24 04:47PM	Corcept: Q4 Earnings Snapshot (Associated Press Finance)
04:44PM	Corcept Therapeutics Inc Reports Significant Revenue Growth and Net Income Increase in Q4 and ... (GuruFocus.com)
04:07PM	Corcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provides Corporate Update (GlobeNewswire)
04:02PM	Corcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical Trial (GlobeNewswire)
Feb-14-24 02:41AM	Jim Simons Bolsters Position in Corcept Therapeutics Inc (GuruFocus.com)
Feb-08-24 04:05PM	Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results, Provide Corporate Update and Host Conference Call (GlobeNewswire)
Jan-29-24 12:10PM	Will Corcept (CORT) Beat Estimates Again in Its Next Earnings Report? (Zacks)
08:00AM	Corcept Appoints Roberto Vieira as President, Oncology (GlobeNewswire)
Jan-09-24 10:48AM	Corcept (CORT) Stock Rises on Upbeat Revenue Guidance for 2024 (Zacks) -8.59%
Jan-08-24 08:00AM	Corcept Therapeutics Provides Financial Update and Announces Stock Repurchase Program (GlobeNewswire) +13.10%
Jan-04-24 09:04AM	Corcept (CORT) Surges 5.1%: Is This an Indication of Further Gains? (Zacks)
Jan-02-24 02:29PM	Corcept Therapeutics Stock Is Down 27%. Its an Ideal Buying Opportunity. (Barrons.com) -25.62%
12:13PM	Corcept Therapeutics, PNM Resources fall; Johnson & Johnson rise, Tuesday, 1/2/2024 (Associated Press Finance)
11:27AM	Corcept (CORT) Falls on Loss of Korlym Patent Lawsuit to Teva (Zacks)
08:00AM	Court Finds Corcept Therapeutics' Patents Not Infringed (GlobeNewswire)
Dec-29-23 06:43PM	Corcept loses patent spat against Teva, shares tumble (Reuters)
06:34PM	UPDATE 2-Corcept loses patent spat against Teva, shares tumble (Reuters)
06:14PM	US judge rules in favor of Teva over patent spat with Corcept (Reuters)

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company. It engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Swisher Daniel N JR	Director	Dec 10 '24	Option Exercise	12.13	2,200	26,686	2,200	Dec 12 04:59 PM
Swisher Daniel N JR	Director	Dec 10 '24	Sale	59.46	2,200	130,812	0	Dec 12 04:59 PM
Swisher Daniel N JR	Director	Dec 10 '24	Proposed Sale	59.46	2,200	130,812		Dec 10 10:00 AM
Robb Gary Charles	Chief Business Officer	Nov 22 '24	Sale	56.20	2,609	146,626	20,163	Nov 26 06:16 PM
Lyon Joseph Douglas	See Remarks	Nov 22 '24	Sale	56.72	1,411	80,032	8,494	Nov 26 06:13 PM
Lyon Joseph Douglas	Officer	Nov 22 '24	Proposed Sale	56.72	1,411	80,032		Nov 22 02:36 PM
Robb Gary Charles	Officer	Nov 22 '24	Proposed Sale	56.20	2,609	146,626		Nov 22 11:41 AM
Swisher Daniel N JR	Director	Nov 11 '24	Option Exercise	12.13	2,200	26,686	2,200	Nov 13 08:06 PM
Swisher Daniel N JR	Director	Nov 11 '24	Sale	59.88	2,200	131,736	0	Nov 13 08:06 PM
Swisher Daniel N JR	Director	Nov 11 '24	Proposed Sale	59.88	2,200	131,736		Nov 12 08:21 AM
Guyer William	Chief Development Officer	Nov 01 '24	Option Exercise	21.65	6,606	143,020	12,402	Nov 05 07:48 PM
Guyer William	Chief Development Officer	Nov 04 '24	Option Exercise	21.65	3,394	73,480	9,190	Nov 05 07:48 PM
Guyer William	Chief Development Officer	Nov 01 '24	Sale	48.97	6,606	323,496	5,796	Nov 05 07:48 PM
Guyer William	Chief Development Officer	Nov 04 '24	Sale	48.97	3,394	166,204	5,796	Nov 05 07:48 PM
Guyer William	Officer	Nov 01 '24	Proposed Sale	48.97	10,000	489,700		Nov 01 12:55 PM
Guyer William	Chief Development Officer	Oct 01 '24	Option Exercise	21.65	10,000	216,500	15,796	Oct 03 04:27 PM
Guyer William	Chief Development Officer	Oct 01 '24	Sale	46.28	10,000	462,800	5,796	Oct 03 04:27 PM
Robb Gary Charles	Chief Business Officer	Oct 01 '24	Option Exercise	3.29	11,000	36,190	33,772	Oct 01 07:55 PM
Robb Gary Charles	Chief Business Officer	Oct 01 '24	Sale	46.28	11,000	509,080	22,772	Oct 01 07:55 PM
Robb Gary Charles	Officer	Oct 01 '24	Proposed Sale	46.28	11,000	509,080		Oct 01 12:55 PM
Guyer William	Officer	Oct 01 '24	Proposed Sale	46.28	10,000	462,800		Oct 01 12:44 PM
Guyer William	Chief Development Officer	Sep 03 '24	Option Exercise	21.65	10,000	216,500	16,039	Sep 05 08:04 PM
Guyer William	Chief Development Officer	Sep 03 '24	Sale	35.30	10,000	353,000	6,039	Sep 05 08:04 PM
Guyer William	Officer	Sep 03 '24	Proposed Sale	35.30	10,000	353,000		Sep 03 11:33 AM
Robb Gary Charles	Chief Business Officer	Aug 26 '24	Sale	35.71	3,101	110,737	23,190	Aug 28 05:59 PM
Robb Gary Charles	Officer	Aug 26 '24	Proposed Sale	35.71	3,101	110,737		Aug 26 03:37 PM
Swisher Daniel N JR	Director	Aug 01 '24	Option Exercise	5.86	150	879	150	Aug 05 07:10 PM
Swisher Daniel N JR	Director	Aug 01 '24	Sale	38.50	150	5,775	0	Aug 05 07:10 PM
Guyer William	Chief Development Officer	Aug 01 '24	Option Exercise	21.65	10,000	216,500	16,039	Aug 05 06:56 PM
Guyer William	Chief Development Officer	Aug 01 '24	Sale	38.67	10,000	386,700	6,039	Aug 05 06:56 PM
Hunt Hazel	Chief Scientific Officer	Aug 01 '24	Option Exercise	2.81	60,000	168,600	153,354	Aug 05 06:31 PM
BELANOFF JOSEPH K	Chief Executive Officer	Jul 31 '24	Option Exercise	3.29	450,000	1,480,500	798,811	Aug 02 04:42 PM
Swisher Daniel N JR	Director	Aug 01 '24	Proposed Sale	38.50	150	5,775		Aug 01 01:36 PM
Guyer William	Officer	Aug 01 '24	Proposed Sale	38.67	10,000	386,700		Aug 01 11:26 AM
Lyon Joseph Douglas	See Remarks	Jul 01 '24	Option Exercise	11.35	5,000	56,750	14,290	Jul 03 05:16 PM
Lyon Joseph Douglas	See Remarks	Jul 01 '24	Sale	32.49	5,000	162,452	9,290	Jul 03 05:16 PM
Guyer William	Chief Development Officer	Jul 01 '24	Option Exercise	21.65	10,000	216,500	16,039	Jul 03 05:13 PM
Guyer William	Chief Development Officer	Jul 01 '24	Sale	32.49	10,000	324,900	6,039	Jul 03 05:13 PM
Robb Gary Charles	Chief Business Officer	Jul 01 '24	Option Exercise	3.29	11,000	36,190	37,291	Jul 03 04:54 PM
Robb Gary Charles	Chief Business Officer	Jul 01 '24	Sale	32.49	11,000	357,390	26,291	Jul 03 04:54 PM
Swisher Daniel N JR	Director	Jul 01 '24	Option Exercise	5.86	2,200	12,892	2,200	Jul 03 04:54 PM
Swisher Daniel N JR	Director	Jul 01 '24	Sale	32.81	2,200	72,182	0	Jul 03 04:54 PM
Robb Gary Charles	Chief Business Officer	Jun 04 '24	Option Exercise	3.29	14,000	46,060	37,115	Jun 06 06:21 PM
Lyon Joseph Douglas	See Remarks	Jun 03 '24	Option Exercise	11.35	5,000	56,750	12,314	Jun 05 09:15 PM
Lyon Joseph Douglas	See Remarks	Jun 03 '24	Sale	30.18	5,000	150,916	7,314	Jun 05 09:15 PM
Swisher Daniel N JR	Director	Jun 03 '24	Option Exercise	5.86	2,200	12,892	2,200	Jun 05 09:15 PM
Swisher Daniel N JR	Director	Jun 03 '24	Sale	30.21	2,200	66,462	0	Jun 05 09:15 PM
Guyer William	Chief Development Officer	Jun 03 '24	Option Exercise	19.26	10,000	192,600	16,039	Jun 05 09:11 PM
Guyer William	Chief Development Officer	Jun 03 '24	Sale	32.00	10,000	320,000	6,039	Jun 05 09:11 PM
Robb Gary Charles	Chief Business Officer	May 28 '24	Option Exercise	3.29	11,000	36,190	31,203	May 30 09:00 PM
Robb Gary Charles	Chief Business Officer	May 28 '24	Sale	30.39	11,000	334,294	20,203	May 30 09:00 PM
Guyer William	Chief Development Officer	May 28 '24	Option Exercise	19.26	30,000	577,800	36,039	May 30 08:03 PM
Guyer William	Chief Development Officer	May 28 '24	Sale	32.00	30,000	960,000	6,039	May 30 08:03 PM
Maduck Sean	See Remarks	May 13 '24	Option Exercise	3.88	50,000	194,000	135,222	May 15 08:32 PM
Maduck Sean	See Remarks	May 13 '24	Sale	28.00	50,000	1,400,000	85,222	May 15 08:32 PM
Lyon Joseph Douglas	See Remarks	May 09 '24	Option Exercise	11.35	7,227	82,026	14,541	May 13 09:32 PM
Lyon Joseph Douglas	See Remarks	May 09 '24	Sale	26.00	7,227	187,902	7,314	May 13 09:32 PM
Lyon Joseph Douglas	See Remarks	May 02 '24	Option Exercise	11.35	10,830	122,920	18,144	May 06 08:23 PM
Lyon Joseph Douglas	See Remarks	May 02 '24	Sale	26.00	10,830	281,580	7,314	May 06 08:23 PM
Swisher Daniel N JR	Director	May 01 '24	Option Exercise	5.86	2,200	12,892	2,200	May 03 04:05 PM
Swisher Daniel N JR	Director	May 01 '24	Sale	23.09	2,200	50,798	0	May 03 04:05 PM
MAHONEY DAVID L	Director	Apr 10 '24	Option Exercise	1.74	30,000	52,200	30,000	Apr 12 07:00 PM
Lyon Joseph Douglas	See Remarks	Apr 04 '24	Option Exercise	11.35	5,443	61,778	12,757	Apr 08 06:16 PM
Lyon Joseph Douglas	See Remarks	Apr 04 '24	Sale	26.00	5,443	141,524	7,314	Apr 08 06:16 PM
Lyon Joseph Douglas	See Remarks	Apr 01 '24	Option Exercise	11.35	500	5,675	7,814	Apr 03 08:00 PM
Lyon Joseph Douglas	See Remarks	Apr 01 '24	Sale	26.01	500	13,004	7,314	Apr 03 08:00 PM
Swisher Daniel N JR	Director	Apr 01 '24	Option Exercise	5.86	2,200	12,892	2,200	Apr 03 07:38 PM
Swisher Daniel N JR	Director	Apr 01 '24	Sale	25.30	2,200	55,660	0	Apr 03 07:38 PM
Maduck Sean	See Remarks	Mar 27 '24	Option Exercise	3.88	25,953	100,698	111,175	Mar 29 02:12 PM
Maduck Sean	See Remarks	Mar 27 '24	Sale	25.01	25,953	649,025	85,222	Mar 29 02:12 PM
Maduck Sean	See Remarks	Mar 18 '24	Option Exercise	3.88	17,219	66,810	92,441	Mar 20 05:09 PM
Maduck Sean	See Remarks	Mar 19 '24	Option Exercise	2.61	10,000	26,100	85,222	Mar 20 05:09 PM
Maduck Sean	See Remarks	Mar 18 '24	Sale	25.00	17,219	430,475	75,222	Mar 20 05:09 PM
Swisher Daniel N JR	Director	Mar 01 '24	Option Exercise	5.86	2,200	12,892	2,200	Mar 05 09:02 PM
Swisher Daniel N JR	Director	Mar 01 '24	Sale	23.59	2,200	51,898	0	Mar 05 09:02 PM
Lyon Joseph Douglas	Chief Accounting Officer	Feb 16 '24	Option Exercise	11.35	1,000	11,350	7,774	Feb 21 09:11 PM
Lyon Joseph Douglas	Chief Accounting Officer	Feb 16 '24	Sale	26.00	1,000	26,000	6,774	Feb 21 09:11 PM
Maduck Sean	See Remarks	Feb 16 '24	Option Exercise	3.61	27,068	97,810	101,523	Feb 20 08:06 PM
Maduck Sean	See Remarks	Feb 15 '24	Option Exercise	3.29	4,760	15,660	79,215	Feb 20 08:06 PM
Maduck Sean	See Remarks	Feb 16 '24	Sale	25.97	27,068	702,905	74,455	Feb 20 08:06 PM
Maduck Sean	See Remarks	Feb 15 '24	Sale	25.00	4,760	119,000	74,455	Feb 20 08:06 PM
Swisher Daniel N JR	Director	Feb 01 '24	Option Exercise	5.86	2,200	12,892	2,200	Feb 02 05:39 PM
Swisher Daniel N JR	Director	Feb 01 '24	Sale	22.00	2,200	48,400	0	Feb 02 05:39 PM
Hunt Hazel	Chief Scientific Officer	Jan 08 '24	Option Exercise	3.02	50,000	151,000	123,146	Jan 12 08:06 PM
Swisher Daniel N JR	Director	Jan 02 '24	Option Exercise	5.86	2,200	12,892	2,200	Jan 04 07:14 PM
Swisher Daniel N JR	Director	Jan 02 '24	Sale	22.11	2,200	48,642	0	Jan 04 07:14 PM
Guyer William	Chief Development Officer	Dec 22 '23	Option Exercise	19.26	10,000	192,600	16,643	Dec 22 07:29 PM
Guyer William	Chief Development Officer	Dec 22 '23	Sale	32.00	10,000	320,000	6,643	Dec 22 07:29 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CORT

Corcept Therapeutics Inc

Upgrade your FINVIZ experience